Former MediVet sales director Michael Kegley, Jr. was sentenced to 30 months in federal prison Jan. 6 after he entered a plea of guilty to one count of drug adulteration and misbranding in the ongoing case around a series of racehorse doping rings, reports the Thoroughbred Daily News. Among the misbranded and adulterated performance-enhancing drugs marketed and sold by Kegley was “SGF-1000.”
During his plea hearing in July, Kegley stated: “Beginning in 2016, I was an independent contractor for a company, MediVet Equine. We sold a variety of products, including SGF-1000. I sold these products to veterinarians, horse trainers. When I did that I knew there was no medical prescription for those products. Also at the time, I knew that the product was not manufactured in an FDA approved facility, nor was it approved for sale by the FDA.”
Kegley's brother-in-law, Dr. Kristian Rhein, received a three-year prison sentence on Wednesday for his involvement in the same case. Trainer Jorge Navarro was last month sentenced to five years in prison.
The sentence requires Kegley to forfeit $3,310,490, equal to the amount of the illegal substances the government seized, but a court order states that if he makes the payment within two years of his prison release he will only need to pay $192,615.
According to the allegations contained in the Superseding Information, the prior Indictments[1], other filings in this case, and statements during court proceedings:
The charges in the Navarro case arise from an investigation of widespread schemes by racehorse trainers, veterinarians, performance-enhancing drug (“PED”) distributors, and others to manufacture, distribute, and receive adulterated and misbranded PEDs and to secretly administer those PEDs to racehorses competing at all levels of professional horseracing. By evading PED prohibitions and deceiving regulators and horse racing officials, participants in these schemes sought to improve race performance and obtain prize money from racetracks throughout the United States and other countries, including in New York, New Jersey, Florida, Ohio, Kentucky, and the United Arab Emirates (“UAE”), all to the detriment and risk of the health and well-being of the racehorses. Trainers who participated in the schemes stood to profit from the success of racehorses under their control by earning a share of their horses' winnings, and by improving their horses' racing records, thereby yielding higher trainer fees and increasing the number of racehorses under their control. Veterinarians and drug distributors, such as Kegley, who worked as the director of sales for an unregistered distributor of equine drugs, profited from the sale and administration of these medically unnecessary, misbranded, and adulterated substances.
Among the misbranded and adulterated PEDs marketed and sold by Kegley was the drug “SGF-1000,” which was compounded and manufactured in unregistered facilities. SGF-1000 was an intravenous drug promoted as, among other things, a vasodilator capable of promoting stamina, endurance, and lower heart rates in horses through the purported action of “growth factors” supposedly derived from sheep placenta. Despite marketing, selling, and administering SGF-1000, Kegley acknowledged in intercepted calls that he, along with a co-defendant involved in the sale of SGF-1000, did not know the actual contents of SGF-1000. Nevertheless, Kegley's sales of that drug persisted, aided by the claim that SGF-1000 would be untestable in horses by law enforcement.
Read more about SGF-1000 in our previous reporting here and here.
Read more at the Thoroughbred Daily News.
The post Drug Company Sales Director Michael Kegley Sentenced To 30 Months In Prison appeared first on Horse Racing News | Paulick Report.
